Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Pyramid Biosciences General Information
Lead oncology program PBI-200 (a highly CNS penetrant next-generation NTRK inhibitor) is in a global Phase I/II clinical trial in patients with NTRK-fusion driven cancers. GQ1010 (Trop-2 targeted ADC) is scheduled to enter first-in-human trials within the next 12 months from April 2023.
Contact Information
Primary Industry
Biotech
Corporate Office
Waltham, Massachusetts
United States
United States
Drug Pipeline
PBI-200
Phase 1Key Partnerships
GeneQuantum Healthcare, Voronoi Inc.
Pyramid Biosciences Funding
No funding data available
To view Pyramid Biosciences's complete valuation and funding history, request access »